Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of ODM-208 in Metastatic Castration-resistant Prostate Cancer
NCT03436485Phase 2Active, not recruiting
- Sponsor
- Orion Corporation
- Start
- Mar 2018
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of opevesostat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Orion Corporation. Started Mar 2018; status: active, not recruiting.
02
Drugs
opevesostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03436485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436485.